drugset
drugset / Trial / NCT05635461

Relative Bioavailability and Food Effect Study of CVN424

NCT05635461 ↗

Phase 1 Completed 32 enrolled Cerevance Beta, Inc.
RandomizedCrossoverOpen-labelBasic science

Summary

This is a Randomized, Open-Label, Single Oral Dose, Three-Way Cross-Over Trial to Evaluate the Relative Bioavailability of CVN424 Suspension and Tablet Formulations in Healthy Volunteers Under Fasted and Fed Conditions.

Timeline

Start
2022-10-09
Primary completion
2022-11-11
Completion
2022-11-21

Drugs

EvaluationDrugModalityDoseRoute
Comparator SOLENGEPRAS Small molecule 150 mg Oral

Indications

Parkinson disease